 Patients receive recombinant carcinoembryonic antigen-expressing measles virus MV-CEA or oncolytic measles virus encoding thyroidal sodium iodide symporter MV-NIS intraperitoneally over 30 minutes on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity MV-CEA closed as of 06022008. 